Search

Your search keyword '"Horinouchi H"' showing total 691 results

Search Constraints

Start Over You searched for: Author "Horinouchi H" Remove constraint Author: "Horinouchi H"
691 results on '"Horinouchi H"'

Search Results

1. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

4. Efficacy and Safety of First-line Immunotherapy Plus Chemotherapy in Treating Elderly Patients With Extensive-stage Small Cell Lung Cancer

5. EP11.03-08 Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years

6. OA15.06 Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)

7. P2.10-02 Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid)

9. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

10. 124P Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B N2 non-small cell lung cancer: SQUAT trial (WJOG 12119L)

13. 309P Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy

17. 1548P Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy

25. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

32. P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

35. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)

44. 368P Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study

45. 570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC

46. 583P Effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (E7389-LF): Results from the expansion part of a phase I study

Catalog

Books, media, physical & digital resources